This article has been cited by
1Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness"
Kalipso Chalkidou,Ryan Li,Anthony J. Culyer,Amanda Glassman,Karen J. Hofman,Yot Teerawattananon
International Journal of Health Policy and Management.2016;6(4)233
2Disease Control Priorities Third Edition: Time to Put a Theory of Change Into Practice Comment on "Disease Control Priorities Third Edition Is Published: A Theory of Change Is Needed for Translating Evidence to Health Policy"
Wanrudee Isaranuwatchai,Ryan Li,Amanda Glassman,Yot Teerawattananon,Anthony J. Culye,Kalipso Chalkidou
International Journal of Health Policy and Management.2018;8(2)132
3Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?
Claudia G. S. Osorio-de-Castro,Thiago B. Azeredo,Vera L. E. Pepe,Luciane C. Lopes,Sueli Yamauti,Brian Godman,Lars L. Gustafsson
Basic & Clinical Pharmacology & Toxicology.2018;122(4)402
4Essential medicines are still essential
Andy L Gray,Veronika J Wirtz,Ellen F M 't Hoen,Michael R Reich,Hans V Hogerzeil
The Lancet.2015;386(10004)1601
5Essential Medicines in a High Income Country: Essential to Whom?
Mai Duong,Rebekah J. Moles,Betty Chaar,Timothy F. Chen,Esteban Gándara
PLOS ONE.2015;10(12)e0143654